Your Health, We Care
Release date: 2024-08-07 10:06:09 Recommended: 119
Capmatinib is highly selective for c-Met targets, can effectively inhibit the proliferation and migration of c-Met-dependent tumor cells, and can effectively induce apoptosis to achieve anti-tumor activity.
Capmatinib does exist in multiple brands and versions in the market, providing patients with a diverse range of options.
Lucius Pharmaceutical Company in Laos offers a standard dose of 200mg, which is suitable for patients who need treatment at this dose. The 60-piece package size is also convenient for long-term management and use.
The version of Bangladesh Everest Pharmaceuticals is also available in a 200mg dosage in a package of 56 capsules, which may affect the patient's medication frequency or purchase cycle.
As the Rahika brand of Novartis, the product enjoys Novartis' reputation and quality control standards. The same version as Lucius Pharmaceuticals is available in a package of 60 tablets of 200mg for patients who need a stable dose.
As the original drug manufacturer, Novartis Pharma Switzerland offers two versions in different doses to meet the treatment needs of different patients. The 200mg version is the same as the two companies mentioned above, while the 150mg version offers an option for patients who need a lower dose. This diversity helps doctors personalize treatment based on the specific situation of the patient.
Before taking the drug, patients must understand the precautions of the drug in detail to ensure the safety of the drug and avoid the risks caused by blind medication.
Capmatinib may increase sensitivity to light, especially ultraviolet light. Patients should minimize direct exposure to sunlight or ultraviolet light sources during treatment. Take precautions when outdoors, including wearing sun-protective clothing, sunscreen, hats, and sunglasses. Pay close attention to abnormal reactions on your skin and contact a medical professional if necessary.
Monitor for new or worsening symptoms of interstitial lung disease (ILD) or pneumonia, including cough, dyspnea, or chest pain. Once symptoms develop or worsen, a medical evaluation is required. After the diagnosis of ILD or pneumonia, capmatinib should be permanently discontinued.
[Warm Tips] When choosing a capmatinib version, patients should consider several factors, including the reliability of the drug's source, price, dosage needs, and physician recommendations.
